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Cholesterol can be a major carbon source for Mycobacterium
tuberculosis during infection, both at an early stage in the macro-
phage phagosomeand laterwithin thenecrotic granuloma.KstR is
a highly conserved TetR family transcriptional repressor that reg-
ulates a large set of genes responsible for cholesterol catabolism.
Many genes in this regulon, including kstR, are either induceddur-
ing infection or are essential for survival ofM. tuberculosis in vivo.
In this study, we identified two ligands for KstR, both of which are
CoA thioester cholesterol metabolites with four intact steroid
rings. Ametabolite inwhich one of the rings was cleavedwas not a
ligand.We confirmed the ligand-protein interactions using intrin-
sic tryptophan fluorescence and showed that ligand binding
strongly inhibitedKstR-DNAbinding using surface plasmon reso-
nance (IC50 for ligand  25 nM). Crystal structures of the ligand-
free formofKstR showvariability in thepositionof theDNA-bind-
ing domain. In contrast, structures of KstRligand complexes are
highly similar to each other and demonstrate a position of the
DNA-binding domain that is unfavorable for DNA binding. Com-
parison of ligand-bound and ligand-free structures identifies resi-
dues involved in ligand specificity and reveals a distinctivemecha-
nism by which the ligand-induced conformational change
mediates DNA release.
Tuberculosis remains a global threat to human health due
to the emergence of extremely drug-resistant forms ofMyco-
bacterium tuberculosis and co-infection with HIV (1). Eluci-
dation of metabolic networks essential to the pathogenesis
of M. tuberculosis is an important part of the quest to iden-
tify new drug target candidates that can be exploited to
tackle extremely drug-resistant tuberculosis. In particular,
M. tuberculosis possesses an unusual ability to metabolize
lipids, and its genome is heavily orientated toward this task
with the involvement of a remarkable number of genes,
250, constituting around 6% of its genome (2).
Cholesterol, the dominant lipid accumulated inM. tubercu-
losis-induced foamymacrophages, is a key growth substrate for
M. tuberculosis in the intraphagosomal environment and is also
important to the bacterium in necrotizing granulomas in late
stage infection (3–5).M. tuberculosis is capable of utilizing cho-
lesterol as a sole carbon source for both energy synthesis and
assimilation into membrane lipids (3, 6). Many genes in the
cholesterol degradation pathway are up-regulated or are essen-
tial forM. tuberculosis infection in variousmodels of disease (3,
4, 7–11). Disruption of genes encoding cholesterol catabolic
enzymes, either through genetic manipulation or chemically,
inhibits growth of the bacterium in both macrophage and ani-
mal models, and in vitro experiments suggest that this growth
inhibition may be due to the toxicity of accumulated interme-
diates (4, 9, 12).
The cholesterol degradation pathway is regulated by two
TFRs,7 KstR and KstR2 (13, 14). These regulate two distinct
regulons and negatively autoregulate their own expression.
KstR regulates the expression of the genes involved in the trans-
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membrane transport of cholesterol, -oxidation of the choles-
terol aliphatic side chain, and opening and removal of steroidal
rings A and B, whereas KstR2 regulates subsequent steps that
presumably degrade the C and D rings of the steroid (15). As is
common in TFRs, KstR and KstR2 show highest sequence sim-
ilarity in their N-terminal DNA-binding domains (DBDs) and
are less similar in their C-terminal ligand-binding domains
(LBDs). KstR and KstR2 act independently of each other, indi-
cating that they are triggered by different ligands (14). Intrigu-
ingly, KstR itself is essential for survival in mouse models (16).
Although the reason for the essentiality of KstR is not fully
understood, it may be because cholesterol catabolism is essen-
tial for virulence (12).
TetR family members are known for their ability to bind
diverse ligands: one of the best characterized examples is QacR,
the regulator of a multidrug export pump, which responds to
more than 16 different ligands (17, 18). The unusually large
regulon of KstR (74 genes inM. tuberculosis) and the presence
of genes within it that are involved in growth on palmitate sug-
gest that the repressormay also control themetabolismof lipids
other than just cholesterol (13) and is therefore likely to be
induced by more than one compound. In the first investigation
of possible cognate ligands for KstR in Mycobacterium smeg-
matis, García-Ferna´ndez et al. (19) determined that cholesterol
and cholest-4-en-3-one, the entry compound and initialmetab-
olite of the pathway (Fig. 1), respectively, were unable to induce
the release of KstR from its operator. In contrast,M. smegmatis
KstR primarily responded to 3-oxocholest-4-en-26-oic acid
(3OChA). Cholesterol is practically insoluble in water, so the
extent to which these results are affected by the relative solu-
bility of these compounds is unclear. Curiously, M. smegmatis
KstR appears unaffected by 4-androstene-3,17-dione and 1,4-
androstadiene-3,17-dione, which are further metabolized ste-
rol compounds that lack an alkyl chain.
Casabon et al. (15) established that the cognate ligand for
M. tuberculosisKstR2 is the coenzyme A (CoA) thioester of the
two-ring sterol metabolite 3a-H-4(3-propanoate)-7a-meth-
ylhexahydro-1,5-indanedione (HIP). The molecular determi-
nants of this interaction were delineated in a subsequent study
by Crowe et al. (20). We therefore set out to establish whether
the CoA thioester adducts of early metabolites of cholesterol
would be functional inducers of KstR regulation and to under-
stand the molecular details of their mode of action.
Experimental Procedures
Chemical and Reagents—ATP, CoASH, and 2-hydroxypro-
pyl--cyclodextrin were purchased from Sigma-Aldrich. 3OChA,
3-oxo-23,24-bisnorchol-4-en-22-oic acid (4-BNC), and 3-hy-
droxy-9-oxo-9,10-seco-23,24-bisnorchola-1,3,5(10)-trien-22-
oic acid were purchased from Steraloids, Inc. (Newport, RI).
Restriction enzymes and the Expand High Fidelity PCR System
were purchased from New England Biolabs (Ipswich, MA) and
Roche Applied Science, respectively. Oligonucleotides for
amplifying KstR were purchased from Integrated DNA Tech-
nologies (San Diego, CA). All other reagents were of HPLC or
analytical grade. Water for buffers was purified using a Barn-
stead Nanopure Diamond system (Dubuque, IA) to a resistivity
of at least 18megaohmscm1. Recombinant tobacco etch virus
protease was expressed and purified in house. HiTrap chelating
affinity columns were purchased from Amersham Biosciences.
Amicon Ultra centrifugal filters were purchased from Merck
Millipore. Size exclusion columns and surface plasmon reso-
nance (SPR) consumables were purchased fromGEHealthcare.
Preparation of CoA Thioesters—3-Oxo-23,24-bisnorchol-4-
en-22-oyl-CoA (4-BNC-CoA), 3-oxocholest-4-en-26-oyl-CoA
(3OCh-CoA), and 3-hydroxy-9-oxo-9,10-seco-23,24-bisnor-
chola-1,3,5(10)-trien-22-oyl-CoA (3-HSBNC-CoA) were pre-
pared essentially as described previously (21–23). M. tubercu-
losis His6-FadD19 was obtained and used to synthesize
3OCh-CoA from 3OChA as described previously (23). Briefly, 0.6
mg of 3OCh dissolved in 25% low molecular weight 2-hydroxy-
propyl--cyclodextrin was mixed with 2 mg ofM. tuberculosis
FadD19 for 13 h at room temperature. Proteins were removed
by precipitation with methanol at 4 °C for an hour. This mix-
ture was filtered before being deposited onto a 60 mg/3 ml
Strata-X 33-m polymeric reversed phase solid phase extrac-
FIGURE 1. Schematic of cholesterol degradation in M. tuberculosis. A–D
refer to rings A–D.
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tion column (Phenomenex, Torrance, CA) conditioned with 2
ml of methanol and equilibrated with 2 ml of Nanopure water.
The column was washed with 1.5 ml of 5% methanol and then
with 1 ml of 90% methanol. Unreacted 3ChOA was removed
using 3 ml of 2% formic acid in acetonitrile followed by 1 ml of
acetonitrile. 3ChO-CoAwas eluted using 4ml of 2% formic acid
in methanol, 1 ml of methanol, and 2.5 ml of 2% formic acid in
methanol in succession. The eluate was dried under N2 and
suspended in 25% -cyclodextrin. The purity of the CoA thio-
ester was verified byHPLC, eluting as a single peak from a Luna
3-mPFP(2) 50 4.6-mm column (Phenomenex) equilibrated
in 0.1 M ammonium acetate, pH 4.5, and run with a linear gra-
dient to 98%methanol. 3ChO-CoAwas quantified by recording
its spectrum in water and assuming the same extinction coeffi-
cient as for 4-BNC-CoA (248  17,200 M1 cm1 (21)). 3a-
H-4(3-propanoyl-CoA)-7a-methylhexahydro-1,5-indane-
dione (HIP-CoA) was prepared as reported previously (15, 20).
Gene Cloning—Two plasmid constructs were used in this
study to produce recombinant KstR protein. To produce His6-
tagged KstR, the kstR open reading frame fromM. tuberculosis
(Rv3574) was cloned into pET30a, resulting in the pSK35 plas-
mid as described elsewhere (13). To produce KstR fused with
N-terminally His6-tagged maltose-binding protein (MBP), the
kstR coding region was amplified using a two-step nested PCR
approach using primers listed in Table 1 and cloned into the
expression vector pDEST-566 using the Gateway cloning sys-
tem (Invitrogen) as described in Moreland et al. (24). Briefly,
the first PCR step created a tobacco etch virus cleavage site at
the 5-end of kstR, whereas the second PCR step introduced a
recombination site to both ends of the gene. The final PCR
product was introduced into the donor vector pDONR221
through a recombination step (BP reaction). The resulting con-
struct pDONR221-kstRwas sequence-verified before introduc-
ing the gene into the entry vector pDEST-566 via a second
recombination event (LR reaction). The final constructwas ver-
ified by digestion with the restriction enzyme BsrGI.
Expression and Purification of KstR—Both KstR constructs
were expressed in Escherichia coli BL21(DE3). The E. coli cul-
ture harboring the plasmid was grown in autoinduction
medium ZYM-5052 (25) at 37 °C until A600 reached 0.6–0.8
and then transferred to 18 °C for incubation overnight. Induced
cells were harvested by centrifugation (4000 g, 10 min, 4 °C),
resuspended in lysis buffer (20 mM HEPES, 150 mM NaCl, pH
7.4) containing 10 mM imidazole and passed through a cell dis-
ruptor (ConstantSystem) at 18 kp.s.i. The lysate was centri-
fuged (16,000 g, 30min, 4 °C), and the soluble KstR present in
the supernatant was recovered using a Ni2-charged HiTrap
chelating column. Recombinant KstR was eluted from the col-
umn in the same buffer containing 250 mM imidazole and
mixed with recombinant tobacco etch virus protease to cleave
the affinity tag. To remove the imidazole, the mixture was dia-
lyzed three times against 1000 ml of lysis buffer containing 0.5
mM tris(2-carboxyethyl)phosphine. The mixture was then
passed through the Ni2-charged HiTrap column again. The
cleaved KstR was eluted in lysis buffer containing 20 mM imid-
azole, whereas the cleaved His6 tag and tobacco etch virus pro-
tease remained bound on the column. KstR protein containing
5% other proteins (as judged by SDS-PAGE) was concen-
trated and exchanged back into lysis buffer using an Amicon
Ultra filter (molecular mass cutoff, 10 kDa), snap frozen in liq-
uid nitrogen, and stored at80 °C.
Size Exclusion Chromatography with Multiangle Light Scat-
tering (SEC-MALS)—SEC-MALS was used to determine the
solution molecular mass of KstR. Peak separation was per-
formed using a Superdex 200 10/300GL column connected to a
DionexHPLC system. The columnwas equilibratedwith buffer
containing 20 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM sodium
azide before being loaded with 100 l of 2.5–5 mg/ml KstR.
Multiangle light scattering was measured with an SLD7000
MALS detector and a Shodex RI-101 refractive index detector.
Data were analyzed using PSS WinGPC Unichrom software.
Electrophoretic Mobility Shift Assay (EMSA)—A dsDNA
probe of the M. tuberculosis KstR operator sequence in the
intergenic region between Rv3573c and Rv3574 (Table 1) was
prepared by heating complementary single-strandedDNAolig-
omers to 95 °C and annealing at room temperature in 20 mM
Tris-HCl, 10 mMMgCl2, pH 8.0, 75 mMNaCl as described pre-
viously (20). Binding assays were performed in 20 mM HEPES,
pH 8.0, 10mMMgCl2, 75mMNaCl, 10% glycerol and contained
6 pmol of DNA probe, 12 pmol ofM. tuberculosisKstR, and 0.2
mol of each potential inducer. Assays were incubated at 37 °C
for 30 min prior to being loaded onto a 9% polyacrylamide gel
containing 0.5TBE (50mMTris base, 50mM boric acid, 1 mM
EDTA, pH 8.3) and then run at 105 V for 45 min. Gels were
stained with ethidium bromide (EtBr) and visualized under UV
TABLE 1
Oligonucleotide sequences
The underlined residues indicate the common sequence in the gene-specific and generic primers used for Gateway cloning.
Name Sequence
PCR 1
Forward gene-specific primer 5-GGCAGCGGCGCGGTGGCGGTACTTGCCGAGTCCGAG-3
Reverse gene-specific primer 5-AAAGCTGGGTGCTAGGCGCTGTCTTGATCGCCGAT-3
PCR 2
Forward generic primer 5-GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAAACCTGTATTTTCAGGGCAGCGGCGCG-3
Reverse generic primer 5-GGGGACCACTTTGTACAAGAAAGCTGGGTG-3
EMSA
Forward strand 5-TGCCCACTAGAACGTGTTCTAATAGTGCT-3
Reverse strand 5-AGCACTATTAGAACACGTTCTAGTGGGCA-3
SPR
Forward strand Biotin-5-TGCCCACTAGAACGTGTTCTAATAGTGC-3
Reverse strand 5-GCACTATTAGAACACGTTCTAGTGGGCA-3
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light using an AlphaimagerTM 2200 (Alpha Innotech Corp.) gel
documentation system.
Intrinsic Fluorescence Quenching Assay—The intrinsic tryp-
tophan fluorescence of KstR was measured using a Pistar-180
spectrometer (Applied Photophysics). Protein was excited at
280 nm (bandwidth of 7 nm), and emission spectra were
scanned from300 to 360 nm.A spectralmaximumwas found at
328 nm, and emission at this wavelength was therefore used for
fitting the quenching curve. KstR concentrations in this assay
refer to the monomer. The fluorescence intensities of samples
containing 2MKstR and ligand at a series of concentrations in
buffer (20 mM HEPES, 150 mM NaCl, pH 7.4) were measured
using 10 2-mm Quartz Suprasil cuvettes (Hellma). A solu-
tion of the ligand dissolved in buffer at the highest concentra-
tion used has an absorbance of 0.02 at the excitation and
emissionwavelengths, thus the inner filter effect was negligible.
Themeasured fluorescence intensitieswere fitted to the follow-
ing equation developed from a simple 1:1 binding model using
GraphPad Prism 6.0.
F  Fmax

	
L Kd 
M0 	
L Kd 
M02 4	 
L	 
M0
2	 
M0
	 	Fmax Fmin) (Eq. 1)
where F is the fluorescence in the presence of ligand, Fmax is the
fluorescence in absence of ligand, Fmin is the fluorescence of
ligand-saturated protein, [L] is ligand total concentration (M),
[M]0 is protein concentration (M), and Kd is the dissociation
constant (M).
SPR—SPR was performed using a Biacore T200 (GE Health-
care). To assay KstR-DNA interactions, 28-bp double-stranded
DNA similar to that used in the EMSA was biotinylated at the
5-end of one strand (Table 1) and immobilized on a streptavi-
din sensor chip. The density of DNA on the chip surface was
kept low (less than 100 response units). KstR concentrations in
this assay refer to the dimer. KstR in HBS-EP buffer (10 mM
HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% Surfactant P20, pH
7.4) at a range of concentrations up to 500Mwas injected over
the immobilized DNA surface at a flow rate of 30 l/min for
180 s to collect data for the association phase followed by a
120-s buffer injection at the same flow rate for the dissociation
phase. The surface was regenerated by injecting 0.03% SDS at
50 l/min for 20 s and then washed with a brief injection of
buffer. The equilibrium response was measured 4 s before the
end of the association phase and used to calculate the dissocia-
tion constant Kd. In the ligand inhibition assay, a mixture of 15
nM KstR and ligand at various concentrations was used for the
association phase with the same injection procedure. Curve fit-
ting to SPR data was performed using a one-site binding equa-
tion with specific and nonspecific interaction components
using GraphPad Prism 6.0.
Crystallization and X-ray Data Collection—All crystals in
this study were grown at 18 °C using the vapor diffusion
method in hanging drop (free KstR) or sitting drop (KstRligand
complex) format. Purified KstR at 5 mg/ml was mixed with
crystallization mother liquor at a 1:1 volume ratio to make a
4-l (His6-KstR construct) or 2-l drop (MBP-fused con-
struct). For proteinligand complexes, KstR was mixed with its
ligand at a final concentration of 220 M KstR monomer and
250 M ligand, and the mixture was left at room temperature
for 3 h before being dispensed with crystallization mother liq-
uor in a 1:1 volumetric ratio to make 0.4-l drops using a Car-
tesianHoneybee nanoliter dispensing robot. Except for crystals
of apoprotein, which were cryoprotected with an addition of
25% glycerol to its mother liquor, crystals were mounted and
flash cooled in their mother liquor. X-ray diffraction data from
all crystals were collected using beamline MX2 at the Austra-
lian Synchrotron on an ADSC QUANTUM 315R CCD detec-
tor. Data were indexed and integrated using iMosflm (26) or
XDS (27) and then scaled and merged using Aimless in the
CCP4 program suite (28).
Structure Determination and Refinement—The initial struc-
ture of KstR (from the MBP-KstR construct) was solved by
molecular replacement using BALBES (29) (CCP4 program
suite). Chain A of a TetR transcriptional regulator from Rhodo-
coccus sp. RHA1 (Protein Data Bank code 3BJB) was used as the
searchmodel. Model building was done using ARP/wARP (30),
and refinement was initially carried out using Refmac5 (31).
The structurewas further refinedwith diffraction data obtained
at 2 and 1.85 Å using phenix.refine (32) and AutoBuster (33).
For the ligand-bound structures, the apoprotein structure was
used for molecular replacement, and the obtained solutions
were then input to PHENIX AutoBuild (34) to improve model
quality and refined using phenix.refine. Initial ligand geometry
was generated using the Coot Ligand Builder (35), ligand geo-
metrical restraints were generated using eLBOW (36), and
manual rebuilding was carried out using Coot (35). Structures
were visualized and illustrated using PyMOL (37).
Results
Analysis of KstR-DNA Interactions—We reported previously
that M. tuberculosis KstR forms a dimer in solution (13),
whereas it has been reported that a small fraction of monomer
might also exist in a solution of purified M. smegmatis KstR
(19). SEC-MALS analysis of purified M. tuberculosis KstR
showed a single, homogeneous peak of molecular mass 44.5
kDa (Fig. 2), which is very close to the theoretical mass of the
KstR dimer (44.6 kDa). No peak consistent with the predicted
size of the protein monomer was observed, demonstrating that
M. tuberculosis KstR is an obligatory homodimer.
In our previous study, KstR bound as a dimer to its target
DNA, a 28-bp fragment from the intergenic region between the
open reading frames Rv3573c and Rv3574 (kstR) in the
M. tuberculosis genome (13). In this study, the affinity of KstR
for its target DNA was quantitated by SPR using a biotinylated
version of the same 28-bp (17.2-kDa) DNA fragment immobi-
lized on the surface of a streptavidin sensor chip. Under these
conditions, M. tuberculosis KstR showed relatively fast associ-
ation and dissociation kinetics with a global Kd of 9.9 0.6 nM
(Fig. 3A). However, the kinetic data could not be fitted to a
simple Langmuir model, indicating a more complex mode of
interaction. Themaximumresponse at saturated binding (i.e. at
500 nMKstR dimer) correlates with the amount of immobilized
DNA in a 1:1 stoichiometry of DNA duplex:KstR dimer (i.e. 37
Structure of Ligand-bound KstR
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response units of KstR dimer and 18 response units of DNA
versus 45 kDa of KstR dimer and 18 kDa of DNA).
The Endogenous Ligands of KstR Are Thioesters of Cholesterol
Side-chain Degradation Products—To identify the likely
endogenous effectors ofM. tuberculosis KstR, EMSAs of KstR-
DNA binding were performed in the presence of a selection of
six potential effector molecules. Among these, only 4-BNC-CoA
and3OCh-CoAreleasedKstR from its targetDNA(Fig. 3B). Curi-
ously, neither 4-BNC nor 3OChA induced DNA release despite
the previous report that the latter is able to bind toM. smegmatis
KstR (19). Moreover, neither CoASH nor HIP-CoA, a down-
stream metabolite in which the side chain and ring A are com-
pletely degraded (15, 20), acted as KstR effectors. Finally,
3-HSBNC-CoA, the equivalent of 4-BNC-CoAwith a cleaved ring
B, also did not act as an effector (Fig. 3B). Together, these results
suggest that the four steroid rings and the CoA esterified side-
chainmoiety are required for a functional interactionwith 3OCh-
CoA having a greater effect than 4-BNC-CoA.
To determine the affinity of the interactions, the intrinsic
tryptophan fluorescence of KstRwasmonitored in the presence
of various concentrations of both identified cognate ligands
(Fig. 3C). KstR has two tryptophan residues in its sequence, one
of which (Trp-164) flanks the potential ligand-binding pocket
and thus is positioned to have its fluorescence modified when
the pocket is occupied. A strong quenching effect (up to 70% of
the fluorescence intensity at 328 nm) was observed in the pres-
ence of both ligands. Fitting quenching curves to a one-site
binding model gave calculated Kd values of 60 20 and 280
50 nM for 3OCh-CoA and 4-BNC-CoA, respectively. No coop-
erativity was observed, suggesting that the two binding sites of
the dimer have equal and independent affinity toward both
ligands. The assay was in agreement with the EMSA results as
FIGURE 2. SEC-MALS analysis of KstR. KstR was eluted in a single peak as
detected by refractive index detection (solid and dashed lines represent sam-
ples loaded at 2.5 and 5.0mg/ml, respectively). Calculatedmolar mass across
the peaks (filled and empty circles at 2.5 and 5.0mg/ml, respectively) indicates
a dimeric form of KstR in solution. The graph shows the complete elution
range of the Superdex 200 10/300 GL column, and the inset shows an
enlarged region around the peak.
FIGURE 3. Analysis of the interaction of KstR with DNA and ligands. A, global fitting of SPR equilibrium response of the KstR-DNA interaction. Change in
response units (RU) at equilibrium is plotted against concentration of KstR dimer. B, EMSA to identify KstR ligands. All lanes contain 0.6M DNA probe and 1.2
M KstR monomer plus either 20 M possible effector or 600 ng of nonspecific (NS) (salmon sperm) DNA. C, intrinsic fluorescence of KstR in the presence of
3OCh-CoA (circles, solid line) or 4-BNC-CoA (squares, dashed line). Samples contain 2M KstRmonomer and 0–8M ligand.D, SPR analysis of 15 nM KstR dimer
and immobilized DNA in the presence of 3OCh-CoA (circles, solid line) or 4-BNC-CoA (squares, dashed line). Residual binding is normalized against the binding
of KstR in the absenceof ligand. Shownvalues are the averageof triplicate experimentwith two readings for each repeat. Error bars indicate standarddeviation
for all readings.
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the stronger affinity of KstR for 3OCh-CoA is consistent with
the lower concentration of that ligand required to cause DNA
release.
The effect of ligand binding on the interaction of KstR with
its target DNA was investigated using an SPR-based release
assay (Fig. 3D). The same biotinylated 28-bp DNA fragment
was used as a target inmeasuring the inhibitory effect of ligands
on the ability of KstR to bind to DNA. At a fixed concentration
of 30 nMKstR, 3OCh-CoAand 4-BNC-CoA showed IC50 values
of 36  1 and 143  1 nM, respectively. In both cases, strong
inhibition (95% of KstR-DNA binding activity) was obtained,
demonstrating the effective inactivation that these ligands can
impose on KstR. The results confirm that 3OCh-CoA and
4-BNC-CoA are both functionally effective, high affinity
ligands for KstR with 3OCh-CoA exhibiting both a stronger
binding affinity and a more effective induction of DNA release.
The Structure of Ligand-free KstR—The structure of ligand-
free KstR was determined in two different crystal forms (Table
2). In form I (Protein Data Bank code 3MNL), tag-free protein
crystallized in space group P212121 with the asymmetric unit
containing two protein chains. As expected, the global struc-
ture of KstR shows an all-helical protein with nine -helices
arranged into a two-domain architecture (Fig. 4A). The DBD is
located at the N terminus and comprises helices 1–3 of which
helices 2 and 3 form the typical helix-turn-helix motif char-
acteristic of TetR family repressors (37). The rest of the protein
forms a LBD that primarily contacts the DBD via helix 4. A
four-helixbundle,comprisinghelices8and9fromeachmono-
mer, forms the dimer interface. The buried surface between the
two chains is 1099 Å2, or almost 12% of the 9500-Å2 total
surface area of each monomer, as measured by PISA (38), indi-
cating a strong dimer. This is in agreement with the dimeric
arrangement of KstR seen in solution as well as with other
known TetR family structures (e.g. Refs. 39 and 40). Each LBD
in the dimer contains a potential ligand-binding pocket that is
closed by the side chain of Met-104 from helix 5 at one end
and is open to the dimer interface at the opposite end. The
pocket is formed by the 4 helix, the triangle of helices 5–7,
and helix8 and is extensively linedwith hydrophobic residues,
indicating a propensity for binding hydrophobic ligands. The
distance between the two DBDs in the dimer is 42.6 Å (calcu-
lated from C of Tyr-54 in DNA-binding helix 3 in each sub-
unit), which far exceeds the 34-Å distance of two consecutive
major grooves in DNA, suggesting that the conformation seen
in the crystals would be unfavorable for DNA binding. Form II
crystallized in space group I121 with two dimers in the asym-
metric unit. The dimers have high structural similarity to each
other (0.46-Å r.m.s.d. over all main-chain atoms) but differ
somewhat from the dimer seen in form I (1.51- and 1.63-Å
r.m.s.d. between form I and dimer 1 or 2 from form II, respec-
tively). Amolecule of PEG is found bound to the protein in form
II, causing helices 4 and 5 tomove apart slightly and altering
the conformation of Met-104, thus opening the mouth of the
ligand-binding pocket. The distances between the twoDBDs of
TABLE 2
Crystallographic statistics for the KstR structures
Values in parentheses represent the outermost shell of data. CC, correlation coefficient.
Protein Data Bank code 3MNL 5CXG 5CW8 5CXI
Description Apo-KstR KstR in complex with PEG KstR in complex with
3OCh-CoA
KstR in complex with
4-BNC-CoA
Crystallization
Expression construct His6-MBP-KstR His6-KstR His6-KstR His6-KstR
Condition 0.2 M ammonium fluoride,
17.5% PEG 3350
8% PEG 3350, 25% PEG 400,
0.1 M MgCl2, 0.1 M Tris-
HCl, pH 8.5
10 mM NiCl2, 0.1 M Tris,
pH 8.5, 1.0 M Li2SO4
0.1 M MES/imidazole, pH 6.5,
10% PEG 4000, 20%
glycerol, 20 mM carboxylic
acid mixturea
Data collection
Space group P212121 I121 I121 I121
Cell dimension
a, b, c (Å) 4.02, 54.57, 166.0 126.03, 38.38, 154.72 49.69, 67.10, 124.23 49.78, 67.26, 124.23
, , 
 (°) 90.00, 90.00, 90.00 90.00, 111.69, 90.00 9.00, 96.74, 90.00 90.00, 96.79, 90.00
Resolution (Å) 83.08-1.80 37.41-2.10 47.88-2.60 47.88-2.00
No. of unique
reflections
35,558 40,309 12,603 27,478
Rmerge 0.056 (0.606) 0.140 (0.805) 0.197 (0.884) 0.198 (1.095)
I/(I) 26.25 (3.2) 4.6 (1.4) 6.7 (2.3) 9.5 (3.4)
CC1/2 0.999 (0.801) 0.990 (0.669) 0.985 (0.706) 0.993 (0.731)
Completeness (%) 99.9 (99.9) 98.5 (94.6) 100.0 (100.0) 99.6 (99.0)
Redundancy 6.8 (6.4) 3.6 (3.5) 6.4 (6.4) 8.3 (8.3)
Refinement
Resolution (Å) 24.68-1.80 37.41-2.10 47.80-2.60 39.83-2.00
No. of reflections 35,467 40,305 12,603 27,469
Rwork/Rfree 19.1/20.5 21.0/25.8 19.0/23.1 23.8/28.0
No. of atoms
Protein 2,758 5,129 2,635 2,661
Ligand 31 69 63
Water 117 208 72 234
B-factors (Å2)
Protein 30.63 48.68 33.65 26.25
Ligand 49.86 33.05 21.59
Water 37.39 41.97 35.56 32.35
r.m.s.d. from ideal
Bond lengths (Å) 0.009 0.012 0.004 0.011
Bond angles (°) 0.85 0.655 0.75 0.625
a Carboxylic acid mixture: sodium formate, ammonium acetate, trisodium citrate, sodium potassium L-tartrate, sodium oxamate.
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both dimers are also substantially smaller than that found in
form I (38.4 and 37.7 Å), indicating inherent flexibility in the
3-4 loop and that form II may more closely resemble a con-
formation of KstR able to bind DNA (Fig. 4B).
The Structures of KstR in Complex with Its Endogenous
Ligands—The co-crystal structures of KstR in complex with
3OCh-CoA and 4-BNC-CoA were both determined by molec-
ular replacement. Both crystallized in space group I121 with
one KstR dimer in the asymmetric unit. The structures are
highly similar to each other with a r.m.s.d. of 0.24 Å over the
whole dimer. As expected from structures of other TetR family
members (39, 40), theDBDs arewidely spaced in the complexes
with 3OCh-CoA and 4-BNC-CoA, 43.4 and 43.8 Å, respec-
tively. The SPR results described above confirm that these
ligand-bound forms of KstR are incompetent for DNA binding,
and these structures therefore represent KstR in its inactive
form.
Both steroids are positioned in the predicted ligand-binding
pocket of KstR (Fig. 5A), which adopts an open conformation
compared with the ligand-free structures to accommodate the
ligand. The four steroid rings of the 3-oxo-cholest-4-enoylmoi-
ety of both 3OCh-CoA and 4-BNC-CoA make almost entirely
hydrophobic interactions in the pocket and are sandwiched
among helices 4, 5, 7, and 8 (Fig. 5B). The notable excep-
tion is the 3-oxo group, which forms hydrogen bonds with Arg-
158 and a nearby highly coordinated water molecule (Fig. 5C).
As the side chain of Arg-158 also makes a hydrogen bond with
the side-chain carboxyl group of another conserved residues,
Asp-137, the organization of this area is likely to be key to ligand
recognition. Although both the steroidal ring and its aliphatic
side chain are clearly visible and well ordered (the refined
atomicB-factors are less than 20Å2), there is no visible electron
density for the CoAmoiety beyond the sulfur atom. The lack of
electron density for this part of the ligand raises a question of
whether the CoA arm makes contact with the protein and is
required for protein-ligand recognition or whether it is free and
hence functions primarily as a solubilizing group for the ste-
roid. The entrance to the pocket is flanked by4,5, and part of
the 1 helix where there are a number of positively charged
residues (Arg-102, Arg-106, Lys-99, Arg-70, Arg-74, and Lys-
78) that are potential binding sites for the phosphate groups
that are part of the phosphopantothenate component of CoA.
There is weak electron density visible around this area, and
although none of it is strong enough to be assigned with any
certainty to the CoA tail, it seems possible that the tail is local-
ized in this area in a statistically disordered state. Apart from
the interactionmade by the 3-oxo group, no other specific polar
interactionswere found at the keto or sulfide group of the tail of
3OCh-CoA, suggesting that these points do not contribute to
ligand binding.
Comparison of the ligand-free ligand-bound structures of
KstR reveals conformational changes in the global structure of
KstR that can be attributed to ligand binding. The binding
of either ligand induces two changes in the protein: a twist
between the8-9 pair of helices and its dimeric8-9 coun-
terpart at the dimer interface and a positional shift of this heli-
cal pair relative to the rest of the proteinmonomer. The former
movement translates to a change of the angle of contact
between the two subunits in the dimer, whereas the latter
results in a rearrangement within each monomer. The altera-
tion of the dimer interface involves a reorientation of 4.5°
between the 8 helices (Table 3), which causes the DBDs to
move in opposite directions, increasing the separation between
the domains compared with the form II ligand-free structure
(Fig. 6A). In contrast to the variation seen in the ligand-free
structures, both ligand complexes exhibit identical dimer inter-
face angles and very similar distances between DBDs, suggest-
ing a rigidification of the ligand-bound structures. The 5–7
helical bundle, 4 helix, and whole of the DBD in the ligand-
bound structure are very similar to those of the form II ligand-
free structures (r.m.s.d. of 0.589 Å), indicating that they move
together in a concertedmanner during the ligand-induced con-
formational change. In the orientation of the protein that is
depicted (Fig. 6A), this translates to an “upward” shift of the
DBD relative to the dimer interface helical bundle.
FIGURE 4. Structure of ligand-free KstR. A, the dimer of the form I structure
with each monomer colored from blue (N terminus) to red (C terminus) and
helices labeled. The LBD and DBD are indicated. B, superposition of form I
(maroon) and form II (dimer 1; green) overlaid at the central four-helix bundle
composed of helices 8 and 9 from each subunit.
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The local dislocation of these helices appears to be linked to
a ligand-driven flip of the Trp-164 side chain. In ligand-free
KstR, the side chain of Trp-164 is in a relaxed conformation,
adopting a common rotamerwith a 2 dihedral angle of 75–80°
and its aromatic side chain pointing toward the center of the
unoccupied pocket. Upon ligand binding, this side chain rotates
by 120° around the C–C
 bond, adopting a rare rotamer
with a less energetically favorable 2 angle of 40 to 50°
(Table 3). The rotation of the Trp-164 side chain has the effect
of distorting the 5 helix at its C-terminal end, which in turn
FIGURE5.Structureof ligand-boundKstR.A, difference electrondensity in the ligandpocket of KstR indicates thepresenceof bound ligands. Fo Fcelectron
densitymaps (greenmesh; contoured at 2) were calculated prior tomodeling the ligands (gray stickmodel) in structures of KstR determined in complex with
3OCh-CoA and 4-BNC-CoA. B, binding of 4-BNC-CoA (shown as a stick model) into the ligand-binding pocket of KstR (shown as schematic and surface
representations). C, the contacts made by KstR to both 3OCh-CoA and 4-BNC-CoA. Hydrophobic contacts shown in red; hydrogen bonds are shown as green
dashed lines.
TABLE 3
Geometrical measurements of the KstR structures
Form I
Form II
KstR3OCh-CoA KstR4-BNC-CoADimer 1 Dimer 2
Protein Data Bank code 3MNL 5CXG 5CXG 5CW8 5CXI
Distance between C of Tyr-54 and Tyr-54 (Å) 42.6 38.4 37.8 43.4 43.8
Angle between helix 8 and 8 (°)a 85.86 86.65 86.14 81.74 81.74
Dihedral angle 2 of Trp-164 side chain (°)b
Chains A/C 75.9 (75.88%) 79.3 (63.28%) 80.7 (79.08%) 47.3 (1.22%) 48.1 (1.22%)
Chains B/D 78.3 (75.88%) 87.5 (90.98%) 86.7 (90.98%) 42.0 (1.15%) 49.6 (1.22%)
a Orientation vector of each helix is calculated from residues 151 to 172.
b Measured in order of C-C-C
-C1; percentage of rotamer probability as calculated by MolProbity (48) is shown in parentheses.
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displaces the 4 and 6 helices and consequently the DBD (Fig.
6B). The contact between the C-terminal end of the 6 helix
and N terminus of the 8 helix in the other monomer remains
constant with the result that the ligand-induced shift of the 6
helix alters the angle of contact across the dimer interface. The
net result of these displacements is a 6.7-Å shift of the DBD
from its position in the ligand-free structure where it would be
expected to contact the target DNA.
Discussion
In this study, we have analyzed the interaction of KstR with
its cognate DNA and confirmed a 1:1 binding stoichiometry
between theDNAduplex and theKstR dimer. This puts KstR in
the group of TetR family members that bind to their target
DNA sequence motif at a single site (e.g. TetR, SimR, etc. (39,
40)). KstR demonstrates a high affinity for its target DNA with
fast binding kinetics.We have also identified twoCoA thioester
metabolites from early stage cholesterol degradation as ligands
for KstR and characterized their binding affinities for the pro-
tein and their inhibitory effects on DNA binding using surface
plasmon resonance.
KstR regulates most of the enzymes required for side-chain
and A/B ring degradation inM. tuberculosis (13). Its identified
ligands, 3OCh-CoAand4-BNC-CoA, occur early in cholesterol
catabolism, possessing at least three carbons of the aliphatic
side chain. The inability of 3-HSBNC-CoA to act as an effector
suggests that it is unlikely that metabolites produced down-
stream of ring B cleavage act as regulatory ligands. However, it
is difficult to definitively conclude which ligand or ligands
might function as the physiological effectors of KstR: presum-
ably, all of the three-, five-, and eight-carbon intermediates gen-
erated during -oxidation of the side chain would be compe-
tent in this respect. Nevertheless, it is probable thatmetabolites
with a longer side chain are the predominant effectors in vivo,
considering that they are produced first. This idea is supported
by our observation that 3OCh-CoA binds more tightly to KstR
than does 4-BNC-CoA.
The structures of KstRligand complexes reveal a ligand
pocket that recognizes both the shape of a four-ring steroidal
moiety and its highly hydrophobic nature. This is consistent
with the inability of 3-HSBNC-CoA and HIP-CoA to act as
effectors. However, our structural observations do not exclude
the possibility of other four-ring steroids such as cholesterol
and cholest-4-en-3-one acting as ligands for KstR.
3OCh-CoA and 4-BNC-CoA are the main substrates of the
ChsE4ChsE5 andChsE1ChsE2 complexes that initiate cycles 1
and 3 of cholesterol side-chain -oxidation (41). Interestingly,
both of these cycles produce propionyl-CoA,which canbe toxic
for bacterial growth due to inhibition of acetyl-CoAproduction
via pyruvate dehydrogenase (42). To alleviate the burden of this
toxicity, propionyl-CoA can be fed to themethyl citrate cycle or
the methylmalonyl pathway in the presence of vitamin B12 or
utilized in the biosynthesis of cell wall lipids (42–44).
TFRs, which are the most abundant family of transcriptional
regulators inmycobacteria and other actinomycetes (45), make
up a large and structurally variable group of proteins, especially
in their LBDs, which have evolved to accommodate a wide vari-
ety of ligands. The evolution of ligand-specific binding has pro-
gressed in parallel with the allosteric mechanisms that govern
protein activity. As a result, these mechanisms are remarkably
varied among the TetR-like regulators despite their shared
overall architecture. In the majority of TFRs with proposed
inductionmechanisms, the separation of the DBDs is the result
of a pendulum-like movement of helix 4 originating from a
displacement of helix6 upon ligand binding (17, 39, 46, 47). In
contrast, SimR from Streptomyces antibioticus has a distinctive
rigid body rotation about the dimeric interface centermediated
by a dislocation of its 9-10 helical arm, which occludes the
entrance of the ligand pocket of the other subunit in the dimer
(40), and in the case of M. tuberculosis KstR2, ligand binding
pushes the4,6, and7 helices outward, causing a shift in the
DBD in the same direction (20).
For KstR, the distinctive conformational transformation that
can be seen when comparing the ligand-free and ligand-bound
structures differs from all themechanisms described previously
for other TFRs. The binding of the steroid moiety into the
ligand pocket causes changes both within the monomer and
across the dimer interface of KstR. The crystallographic evi-
dence presented here suggests an induction mechanism for
KstR as follows: the binding of a steroid inside the ligand pocket
causes a shift of the 5–7 helical bundle, 4 helix, and DBD as
a whole via a distortion in the 5 helix and the associated flip-
ping of a key tryptophan residue (Trp-164); the concomitant
FIGURE 6. Structural changes in KstR due to ligand binding. A, superposition of monomer structures of ligand-free KstR (green; form II, dimer 1) and KstR in
complex with 3OCh-CoA (blue). The movement of the DBD relative to the 8-9 dimer interface is shown by red arrows. B, the ligand-induced movements of
the KstR monomer are coordinated with a change in the conformation of Trp-164 (shown as a stickmodel).
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dislocation of the 6 helix shifts the 8 helix of the other sub-
unit in the dimer, causing a small rotation of the contacting
angle between subunits at the dimer interface.
Although our EMSAdata indicate the essentiality of the CoA
adduct of both steroid ligands for effective DNA release, no
electron density is observed for the CoAmoiety in either struc-
ture. As the co-crystal complexes were slow to form, we con-
sidered the possibility that the steroid-CoA adductsmight have
hydrolyzed in situ in the crystallization experiments. Direct
analysis of proteinligand complex crystals using mass spec-
trometry was confounded by the presence of PEG from the
crystallization experiments. However, thioesters are known to
be vulnerable to hydrolysis only at the thioester bond, breaking
down to form carboxylic acids and thiols. The electron density
maps of ligand-bound KstR show clear density for the sulfur
atom in all subunits (Fig. 5A), indicating that the thioester bond
is still intact. As no other degradation point of CoA has been
reported, we interpret this to mean that the ligands retained
their integrity in the co-crystal but that the CoA tail is disor-
dered. It is possible that the CoA acts primarily as a solubilizing
agent to increase the pool of steroid that is available for KstR
binding in the cell. Alternatively, the CoA may play a role in
tethering the ligand onto the protein surface via contacts with
the flexible and positively charged residues that surround the
mouth of the ligand-binding pocket. In either case, it appears
not to be contributing any significant specificity to the protein-
ligand interaction. However, the length of the alkyl side chain
contributes to the differential affinities of the two ligands in
a way that is not immediately apparent from inspection of
the structures. However, it is possible that the shorter thio-
ester linker in 4-BNC-CoA causes a sterically unfavorable
positioning of the CoA portion of the ligand, resulting in
weaker binding.
As expected, KstR and KstR2 show overall structural similar-
ity but differ considerably in the details of their interactionwith
their cognate ligands. Both proteins recognize CoA thioester
adducts of cholesterol degradation products, but KstR does not
form specific interactions with the CoAmoiety, which is disor-
dered in the crystal structures reported. This is in marked con-
trast to the extensive protein-CoA interaction seen in the com-
plex between KstR2 and the HIP-CoA (19) and highlights the
diverse ways in which even TFRs that are closely related in
biological function and sequence can interact with and respond
to their cognate ligands.
In conclusion, this study further demonstrates the impor-
tance of CoA thioesters in the regulation of cholesterol catab-
olism and provides a framework of structural information that
can be used to support the future development of druglike com-
pounds targeting KstR. An antagonist of KstR would be
expected to be disadvantageous forM. tuberculosis considering
the essentiality of this regulator for the survival of the bacte-
rium in macrophages. Equally, a compound that enables KstR
to remain bound to DNA even in the presence of its endoge-
nous ligands would also be harmful for M. tuberculosis persis-
tence due to the requirement of the cholesterol metabolic
breakdown pathway during infection. For either purpose, the
mechanism of induction by the endogenous ligands provides a
guideline for the future design of potential therapeutic com-
pounds targeting KstR.
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